Real-world data on PD-1 inhibitor therapy in metastatic melanoma

Area of Science:

• Oncology
• Immunotherapy
• Melanoma Research

Background:

• Phase III trials show PD-1 inhibitors improve survival in metastatic melanoma (MM).
• Generalizability of trial results to routine clinical practice remains uncertain.
• Need to evaluate real-world effectiveness and safety of PD-1 inhibitors in MM.

Purpose of the Study:

• To investigate and describe the clinical efficacy of PD-1 inhibitors in MM patients treated in routine practice.
• To assess the safety profile, including immune-related adverse events (irAEs), of PD-1 inhibitors in a real-world MM cohort.
• To identify factors associated with survival outcomes in MM patients receiving PD-1 inhibitors.

Main Methods:

• Retrospective descriptive study of 116 MM patients treated with PD-1 inhibitors.
• Data collected from medical records at a single institution between September 2015 and August 2017.
• Analysis of overall survival (OS), immune-related adverse events (irAEs), and prognostic factors.

Main Results:

• 12-month OS was 70.2%, with a median OS of 27.9 months.
• BRAF mutation correlated with increased OS; ECOG PS ≥2, elevated LDH, and brain metastases were associated with poorer survival.
• irAEs occurred in 55.2% of patients; grade 3-4 irAEs in 12.9%. Rheumatic irAEs were notably higher (15.5%).
• Occurrence of irAEs was linked to improved OS, irrespective of severity or corticosteroid use.

Conclusions:

• PD-1 inhibitors demonstrate comparable efficacy and safety in routine MM care to clinical trial findings.
• Real-world data supports the benefit of PD-1 inhibitors in metastatic melanoma.
• Understanding irAEs and prognostic factors is crucial for optimizing treatment in clinical practice.